ActoBiotics™
A new class of biopharmaceuticals
During the past two decades, biopharmaceuticals have emerged as a major and fast-growing product class in the pharmaceutical industry, generating a turnover of US$65 billion in 2006 and growing by more than 20% annually.
ActoBiotics™ build on the existing advantages of today’s biotech products, to create the potential blockbuster drugs for tomorrow. They combine the main advantages of protein-based biopharmaceuticals, including high selectivity and low inherent toxicity, with additional benefits such as oral availability and cost-effective manufacturing and formulation.
Some of the competitive advantages of ActoBiotics™ , in comparison with (first generation) conventional chemical drugs and (second generation) biopharmaceuticals, are: